Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice

Biomaterials

Volumn 35, Issue 1, 2014, Pages 456-465

  Zhang, Chi ^a   Wan, Xu ^a   Zheng, Xiaoyao ^a   Shao, Xiayan ^a   Liu, Qingfeng ^a   Zhang, Qizhi ^a   Qian, Yong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

A 1 42 peptide; Alzheimer's disease (AD); Blood brain barrier (BBB); Dual functional nanoparticles

Indexed keywords

ALZHEIMER'S DISEASE; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEM; NEURODEGENERATIVE DISORDERS; POLYLACTIC ACIDS; TARGETED DELIVERY; TARGETING PEPTIDES; TARGETING SYSTEMS;

BLOOD; DRUG DELIVERY; DRUG INTERACTIONS; GLYCOPROTEINS; MAMMALS; NEURODEGENERATIVE DISEASES; OPTIMIZATION; PEPTIDES; SURFACE PLASMON RESONANCE;

NANOPARTICLES;

AMINO ACID DERIVATIVE; MACROGOL; MALEIMIDE; NANOPARTICLE; POLYLACTIC ACID; THIOFLAVINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BLOOD BRAIN BARRIER; BRAIN TISSUE; CELL DENSITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; EX VIVO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; SURFACE PROPERTY;

MUS;

ALZHEIMER'S DISEASE (AD); AΒ(1-42) PEPTIDE; BLOOD-BRAIN BARRIER (BBB); DUAL-FUNCTIONAL NANOPARTICLES;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PLAQUE, AMYLOID; SURFACE PLASMON RESONANCE;

EID: 84887015310     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.063     Document Type: Article

References (43)

1. Brambilla D., Verpillot R., Le Droumaguet B., Nicolas J., Taverna M., Kona J., et al. PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease. ACS Nano 2012, 6(7):5897-5908.
2. Barnes D., Lopez O., Yaffe K. Dementia and Alzheimer's disease 2012, 561-582. The Epidemiology of Aging.
3. Wiesehan K., Stohr J., Nagel-Steger L., van Groen T., Riesner D., Willbold D. Inhibition of cytotoxicity and amyloid fibril formation by a D-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide. Protein Eng Des Sel 2008, 21(4):241-246.
4. Farrall A.J., Wardlaw J.M. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 2009, 30(3):337-352.
5. Winkler J., Ramirez G.A., Kuhn H.G., Peterson D.A., Day-Lollini P.A., Stewart G.R., et al. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann Neurol 1997, 41(1):82-93.
6. Huile G., Shuaiqi P., Zhi Y., Shijie C., Chen C., Xinguo J., et al. Acascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials 2011, 32(33):8669-8675.
7. Gao H., Qian J., Cao S., Yang Z., Pang Z., Pan S., et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 2012, 33(20):5115-5123.
8. Li J., Feng L., Fan L., Zha Y., Guo L., Zhang Q., et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011, 32(21):4943-4950.
9. Gralle M., Botelho M.G., Wouters F.S. Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. JBiol Chem 2009, 284(22):15016-15025.
10. Townsend M., Mehta T., Selkoe D.J. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. JBiol Chem 2007, 282(46):33305-33312.
11. Gravina S.A., Ho L., Eckman C.B., Long K.E., Otvos L.J., Younkin L.H., et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). JBiol Chem 1995, 270(13):7013-7016.
12. Allaman I., Gavillet M., Belanger M., Laroche T., Viertl D., Lashuel H.A., et al. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. JNeurosci 2010, 30(9):3326-3338.
13. Crouch P.J., Harding S.M., White A.R., Camakaris J., Bush A.I., Masters C.L. Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell Biol 2008, 40(2):181-198.
14. Glabe C.G. Structural classification of toxic amyloid oligomers. JBiol Chem 2008, 283(44):29639-29643.
15. De Felice F.G., Ferreira S.T. Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell Mol Neurobiol 2002, 22(5-6):545-563.
16. Wiesehan K., Buder K., Linke R.P., Patt S., Stoldt M., Unger E., et al. Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display. Chembiochem 2003, 4(8):748-753.
17. Bartnik D., Funke S.A., Andrei-Selmer L.C., Bacher M., Dodel R., Willbold D. Differently selected D-enantiomeric peptides act on different Abeta species. Rejuvenation Res 2010, 13(2-3):202-205.
18. van Groen T., Kadish I., Wiesehan K., Funke S.A., Willbold D. Invitro and invivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models. ChemMedChem 2009, 4(2):276-282.
19. Zhang Y., Zhang Q., Zha L., Yang W., Wang C., Jiang X., et al. Preparation, characterization and application of pyrene-loaded methoxy poly(ethylene glycol)-poly(lactic acid) copolymer nanoparticles 2004, 282(12):1323-1328.
20. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010, 75(1):1-18.
21. Zagorski M.G., Yang J., Shao H., Ma K., Zeng H., Hong A. Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity. Methods Enzymol 1999, 309:189-204.
22. Nakamura S., Murayama N., Noshita T., Annoura H., Ohno T. Progressive brain dysfunction following intracerebroventricular infusion of beta(1-42)-amyloid peptide. Brain Res 2001, 912(2):128-136.
23. Christensen R., Marcussen A.B., Wortwein G., Knudsen G.M., Aznar S. Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels. Exp Neurol 2008, 210(1):164-171.
24. Ammassari-Teule M., Middei S., Passino E., Restivo L. Enhanced procedural learning following beta-amyloid protein (1-42) infusion in the rat. Neuroreport 2002, 13(13):1679-1682.
25. Chen J., Zhang C., Liu Q., Shao X., Feng C., Shen Y., et al. Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: invivo and invitro evaluations. JDrug Target 2012, 20(2):174-184.
26. Yuan J. Estimation of variance for AUC in animal studies. JPharm Sci 1993, 82(7):761-763.
27. Zhang Q., Jiang X., Jiang W., Lu W., Su L., Shi Z. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm 2004, 275(1-2):85-96.
28. Wang F., Jiang X., Lu W. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int J Pharm 2003, 263(1-2):1-7.
29. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. JImmunol Methods 1986, 89(2):271-277.
30. Brown R.C., Morris A.P., O'Neil R.G. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 2007, 1130(1):17-30.
31. Omidi Y., Campbell L., Barar J., Connell D., Akhtar S., Gumbleton M. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an invitro blood-brain barrier model for drug uptake and transport studies. Brain Res 2003, 990(1-2):95-112.
32. Arima Y., Toda M., Iwata H. Surface plasmon resonance in monitoring of complement activation on biomaterials. Adv Drug Deliv Rev 2011, 63(12):988-999.
33. Pattnaik P. Surface plasmon resonance. Appl Biochem Biotechnol 2005, 126(2):79-92.
34. Wisniewski H.M., Vorbrodt A.W., Wegiel J. Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease. Ann N Y Acad Sci 1997, 826:161-172.
35. Pardridge W.M. Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimers Dement 2009, 5(5):427-432.
36. Roney C., Kulkarni P., Arora V., Antich P., Bonte F., Wu A., et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. JControl Release 2005, 108(2-3):193-214.
37. Min K., Jo H., Song K., Cho M., Chun Y.S., Jon S., et al. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials 2011, 32(8):2124-2132.
38. Yan H., Wang L., Wang J., Weng X., Lei H., Wang X., et al. Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. ACS Nano 2012, 6(1):410-420.
39. Ko H.Y., Choi K.J., Lee C.H., Kim S. Amultimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin alphavbeta3 and tenascin-C proteins. Biomaterials 2011, 32(4):1130-1138.
40. Bhattacharyya S., Khan J.A., Curran G.L., Robertson J.D., Bhattacharya R., Mukherjee P. Efficient delivery of gold nanoparticles by dual receptor targeting. Adv Mater 2011, 23(43):5034-5038.
41. Scheinin N.M., Aalto S., Kaprio J., Koskenvuo M., Raiha I., Rokka J., et al. Early detection of Alzheimer disease: (1)(1)C-PiB PET in twins discordant for cognitive impairment. Neurology 2011, 77(5):453-460.
42. Peter J., Nestor P.S.J.R. Advances in the early detection of Alzheimer's disease. Nat Rev Neurosci 2004, (5):s34-s41.
43. Ling S., Zhou J., Rudd J.A., Hu Z., Fang M. The recent updates of therapeutic approaches against abeta for the treatment of Alzheimer's disease. Anat Rec (Hoboken) 2011, 294(8):1307-1318.